查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球芯片上的器官市场 - 2023-2030年
市场调查报告书
商品编码
1285084

全球芯片上的器官市场 - 2023-2030年

Global Organ-on-Chip Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球器官芯片市场在2022年达到1.075亿美元，预计到2030年将达到7.967亿美元，在2023-2030年的预测期间，预计将以29.6%的复合增长率增长。器官芯片市场趋势显示，由于疾病发病率的上升和研究与开发的增加，大量采用器官芯片进行药物发现。

器官芯片市场范围包括细分为肝脏芯片模型、肺部芯片模型、肾脏芯片模型、肿瘤模型、心脏芯片模型、定制和多器官芯片模型及其他，这增加了器官芯片的市场份额。器官芯片技术的主要优势是可以创建一个详细的人体模型，在器官或组织层面上有操作反应，从而绕过了动物模型的使用，也极大地提高了个人医疗保健的新药研发业务。

器官芯片的全球市场正在扩大，其因素包括市场发展的不断壮大和在药物开发中替代动物试验的需要，以及器官芯片在药物设计和开发中的支持性指南和批准的存在。2023年1月17日，CN生物创新有限公司宣布FDA和CN生物创新有限公司将第二次扩大合作关系。新的研究将使用PhysioMimix多器官系统来评估多器官MPS及其应用。

市场动态

芯片上的器官模型是动物试验的替代物，推动了芯片上器官市场的增长。

除了真实调查的痛苦之外，实验室中的动物被剥夺了一切现实的和关键的东西，它们被限制在空洞的细胞中，被社会隔离，并受到心理创伤。用于研究的有意识和有情感的生命被当作一次性的实验室设备来对待。大部分的动物研究并没有改善人类的健康，而且动物研究对大多数医学发展的影响有多大也是值得怀疑的。

另外，严格的监管政策和法律的存在正在推动研究人员选择替代动物试验的方法。例如，《动物福利法》，或称AWA，是一项联邦法规，处理在调查机构获得的维护动物的标准。这项法规禁止了大约95%的测试动物，如鸟类、老鼠、鱼类、爬行动物和小鼠，对其余动物只提供最低限度的保护。实验室不需要报告非AWA保护的动物。

不断增长的市场发展为制造商创造了有利可图的机会。

在预期的期限内，全球市场的扩张正被不断增加的市场进步所推动，包括器官芯片行业的产品发布、合作、收购和合併。例如，2022年5月，器官芯片设计公司Emulate Inc.为研究炎症性肠病的调查人员推出了一个更高的产品，其组织模型允许展示免疫细胞如何在体内被触发和分布。

此外，2022年4月，Valo Health公司完成了对TARA Biosystems公司的收购，该公司是一个三维心脏组织模型平台的设计者。Valo打算将TARA的心脏组织芯片整合到一个端到端的药物设计产品中，致力于心血管疾病的研究，由其Opal数据平台推动。同样，在2022年9月，CiRA研究团队开发了一个气道芯片，利用气道组织和血管组织的内皮细胞制定呼吸器官。

替代物的可用性将阻碍市场的增长。

市场上存在着芯片上器官的替代品，这阻碍了整个预期时间内全球市场的扩张。市场上有大量的有机体，它们具有模拟组织和器官生理的类似功能，是在预测期内器官芯片行业扩张的一个重要障碍。

例如，2023年2月，高性能生命科学产品的顶级供应商Molecular Devices, LLC.与成人干细胞衍生器官领域的前沿企业HUB Organoids（HUB）形成合作，旨在帮助下一代3D生物学技术的持续发展，促进临床前到临床药物减量的一步步变化演绎。

COVID-19影响分析

在COVID-19大流行之前，器官芯片在药物设计和开发中的应用是有限的，但在最初阶段，感染者的数量呈指数增长，特定的诊断和治疗方法的不可用性要求增加研究和开发活动，这导致了器官芯片设备的采用增长。

例如，尽管动物原型和单层细胞培养物被用于发病机制的调查和COVID-19治疗的设计，但生物工程芯片上的器官和干细胞器官已经成为两个前沿技术，用于创建生物模拟的体外三维（3D）组织或器官原型。

俄乌战争影响分析

俄罗斯-乌克兰冲突估计对全球器官芯片市场的影响不大，因为该地区的主要市场参与者数量不多。然而，在预测期内，原材料进出口的影响预计对全球器官芯片市场的增长影响不大。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按模式抽查
  • 按应用分类
  • 按终端用户分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 器官芯片模型是动物试验的替代品
      • 越来越多的市场发展
    • 限制因素
      • 替代物的可用性
    • 机会
      • 政府对药物开发和研究的倡议和投资不断增加
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按模型分类

  • 肝脏芯片模型
  • 肺芯片模型
  • 肾脏芯片模型
  • 肿瘤模型
  • 心脏芯片模型
  • 定制和多器官片上模型
  • 其它模型

第8章：按应用分类

  • 药物研发
  • 生理学模型开发
  • 毒理学研究

第九章：按终端用户分类

  • 制药和生物技术公司
  • 学术和研究机构
  • 其他

第十章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
      • 亚太其他地区
  • 中东和非洲
    • 关键区域的动态

第11章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十二章 ：公司简介

  • Emulate Inc.
    • 公司概述
    • 产品组合和描述
    • 财务概况
    • 主要发展情况
  • Mimetas B.V.
  • Insphero
  • Organovo Holdings
  • CN Bio Innovations Ltd
  • BiomimX S.r.l.
  • AxoSim, Inc.
  • Hesperos Inc.
  • TissUse GmbH
  • Nortis, Inc.

第十三章 ：附录

简介目录
Product Code: BT852

Market Overview

The Global Organ-On-Chip Market reached US$ 107.5 million in 2022 and is expected to reach US$ 796.7 million by 2030 and is expected to grow with a CAGR of 29.6% during the forecast period 2023-2030. The organ-on-chip market trends show large adoption of organ-on-chip for drug discovery owing to the rising prevalence of disorders and increasing research and development.

The organ-on-chip market scope comprises models segmented as a liver-on-chip model, lung-on-chip model, kidney-on-chip model, tumor models, heart-on-chip model, custom & multi-organ-on-chip models and others, which has increased the organ-on-chip market share. The main advantage of organ-on-a-chip technology is the facility to create a detailed human model that has operational reactions on the level of organs or tissues, thereby bypassing the usage of animal models, as well as immensely enhancing new drug discovery operations for personal healthcare.

The global market for organ-on-chip is expanding as a result of factors including the increasing market developments and the need for an alternative to animal testing in drug development and the presence of supportive guidelines and approvals for organ-on-chip in drug design and development. On January 17, 2023, CN Bio Innovations Ltd announced that the FDA and CN Bio Innovations Ltd are expanding the partnership for the second time. The new research will use the PhysioMimix Multi-organ System to assess multi-organ MPS and their applications.

Market Dynamics

Organ-On-Chip Model an Alternative to Animal Testing Drives The Growth Of The Organ-on-Chip Market.

Further to the suffering of the true investigations, animals in laboratories are denied everything realistic and crucial to them, they are restricted to empty cells, socially secluded, and psychologically traumatized. The conscious and emotional beings used in research are treated in the same manner as disposable lab equipment. The bulk of animal research does not improve human health, and it is questionable how much of an impact animal research has on most medical developments.

Also, the presence of stringent regulatory policies and laws is pushing researchers to opt for alternatives to animal testing. For instance, the Animal Welfare Act, or AWA, is a federal regulation that handles the criterion of maintenance animals acquire at investigation establishments. This regulation bans approximately 95% of the animals tested like birds, rats, fish, reptiles, and mice, and delivers only minimal protection for the rest. Labs are not needed to report non-AWA-protected animals.

Increasing Market Development Creates Lucrative Opportunities For Manufacturers.

The global market expansion in the anticipated term is being driven by the rising number of market advancements, including product launches, partnerships, acquisitions and mergers in the organ-on-chip industry. For instance, in May 2022, organ-on-a-chip designer Emulate Inc. introduced an elevated offering for investigators researching inflammatory bowel disorder with its tissue model that permits the demonstration of how immune cells are triggered and distributed in the body.

Additionally, in April 2022, Valo Health completed the acquisition of TARA Biosystems, designers of a 3D cardiac tissue modeling platform. Valo intended to integrate TARA's cardiac tissue chips into an end-to-end drug design offering strived at cardiovascular disorder, pushed by its Opal data platform. Similarly, in September 2022, the CiRA research team developed an airway-on-a-chip that enacts respiratory organs employing endothelial cells from airway tissue and vascular tissue.

Availability of Substituents Will Hamper The Growth Of The Market.

The existence of an alternative to organs-on-chips on the market is impeding the expansion of the global market throughout the anticipated time. The market's abundance of organoids, which have the similar function of simulating tissue and organ physiology, is a significant barrier to the expansion of the organ-on-chip industry over the forecast period.

For instance, in February 2023, Molecular Devices, LLC., a top provider of high-performance life science products, and HUB Organoids (HUB), the frontiers in the domain of adult stem cell-derived organoids, formed a collaboration aimed at aiding the persistent development of next-generation 3D biology technologies that facilitates a step-change deduction in pre-clinical to clinical drug attrition.

COVID-19 Impact Analysis

Before the COVID-19 pandemic, organ-on-chip was employed in drug design and development to a limited extent but during the initial period, the number of infected individuals was increasing exponentially, and the unavailability of particular diagnostic and treatments called for increased research and development activities which led to growth in the adoption of organ-on-chip devices.

For instance, although animal prototypes and monolayer cell cultures were employed for pathogenesis investigations and the design of COVID-19 treatment, bioengineered organs-on-chips, and stem cell organoids have appeared as two cutting-edge technologies utilized to create biomimetic in vitro three-dimensional (3D) tissue or organ prototypes.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global organ-on-chip market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global organ-on-chip market growth over the forecast period.

Segment Analysis

The global organ-on-chip market is segmented based on model, application, end user and region.

Drug Discovery From the Application Segment Accounts For 49.4% Of Market Share Owing To Rising Research And Development.

Compared to conventional 2D cell cultures, organ-on-chip platforms can be employed for high-throughput screening of drug candidates in an environment that is more physiologically realistic. Organ-on-chip platforms enable researchers to test and assess the safety and efficacy of drug candidates in a more realistic environment by simulating the microenvironment and functional characteristics of certain organs or tissues. Earlier in the drug discovery process, this can assist uncover possible lead compounds or eliminate hazardous or ineffective candidates, saving time and resources.

The pharmacokinetics (PK) of drug candidates, including their absorption, distribution, metabolism, and excretion (ADME) characteristics, can be studied using organ-on-chip platforms in a more physiologically comparable setting. In addition, almost 44,000 Americans have drug-induced liver infections (DILI). Therefore, creating a liver-on-a-chip technology would be crucial for several diagnostic and therapeutic fields, especially for creating novel treatments for long-term illnesses like hepatitis B, liver cirrhosis, and hepatocellular cancer.

Geographical Analysis

North America Accounted For Approximately 44.8% Of The Market Share Owing To The Strong Presence Of Major Players And Increasing Technological Advancements.

Manufacturers have chances to expand their operations in this region because of the rising demand for organ-on-chip for advancements in North America. The area has many producers and its rapid economic development has raised industrial production of organ-on-chips models. Using cutting-edge technologies, such as 3D bioprinting, Organovo Holdings, Inc., a company that specializes in three-dimensional (3D) biology, successfully took its first inflammatory bowel disease model toward the next stage of target discovery and validation for Crohn's disease.

Furthermore, the growing partnership, adoption and awareness initiatives for organ-on-chip are also contributing to the growth of the regional market in the forecast period. For instance, on May 19, 2021, the collaboration between InSphero AG, a leader in 3D cell-based assay technology, and Hamilton, a leading provider of automated liquid handling equipment, aims to enhance the creation and management of 3D microtissues (spheroids). These factors show the dominance of North America.

Competitive Landscape

The major global players in the organ-on-chip market include: Emulate Inc., Organovo Holdings, Mimetas B.V., AxoSim, Inc., Insphero, CN Bio Innovations Ltd, TissUse GmbH, Hesperos Inc., and Nortis, Inc. among others.

Why Purchase the Report?

  • To visualize the global organ-on-chip market segmentation based on model, application, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of organ-on-chip market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global organ-on-chip market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Model
  • 3.2. Snippet by Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Organ-On-Chip Model an Alternative for Animal Testing
      • 4.1.1.2. Increasing Market Developments
    • 4.1.2. Restraints
      • 4.1.2.1. Availability of Substituents
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing Government Initiatives and Investment in Drug Development and Research
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Model

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
    • 7.1.2. Market Attractiveness Index, By Model
  • 7.2. Liver-On-Chip Model *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Lung-On-Chip Model
  • 7.4. Kidney-On-Chip Model
  • 7.5. Tumor Models
  • 7.6. Heart-On-Chip Model
  • 7.7. Custom & Multi-Organ-On-Chip Models
  • 7.8. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Drug Discovery *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Physiological Model Development
  • 8.4. Toxicology Research

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Pharmaceutical & Biotechnology Companies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Academic & Research Institutes
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Emulate Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Mimetas B.V.
  • 12.3. Insphero
  • 12.4. Organovo Holdings
  • 12.5. CN Bio Innovations Ltd
  • 12.6. BiomimX S.r.l.
  • 12.7. AxoSim, Inc.
  • 12.8. Hesperos Inc.
  • 12.9. TissUse GmbH
  • 12.10. Nortis, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us